These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27548911)

  • 1. Focused Update on Duration of Dual Antiplatelet Therapy for Patients With Coronary Artery Disease.
    Mauri L; Smith SC
    JAMA Cardiol; 2016 Sep; 1(6):733-4. PubMed ID: 27548911
    [No Abstract]   [Full Text] [Related]  

  • 2. Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease.
    Collet JP; Roffi M; Byrne RA; Costa F; Valgimigli M; ; ;
    Eur Heart J; 2018 Jan; 39(3):e1-e33. PubMed ID: 29088328
    [No Abstract]   [Full Text] [Related]  

  • 3. Outcomes with short-term versus long-term antiplatelet dual therapy after drug-eluting stenting: quantifying the equivalence margins.
    Messori A; Fadda V; Maratea D; Trippoli S
    Int J Cardiol; 2014 Mar; 172(2):469-70. PubMed ID: 24461973
    [No Abstract]   [Full Text] [Related]  

  • 4. [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.].
    Valgimigli M; Bueno H; Byrne RA; Collet JP; Costa F; Jeppsson A; Jüni P; Kastrati A; Kolh P; Mauri L; Montalescot G; Neumann FJ; Peticevic M; Roffi M; Steg PG; Windecker S; Zamorano JL
    Kardiol Pol; 2017; 75(12):1217-1299. PubMed ID: 29251754
    [No Abstract]   [Full Text] [Related]  

  • 5. [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: What is new?].
    Öngen Z
    Turk Kardiyol Dern Ars; 2018 Jan; 46(1):1-6. PubMed ID: 29339684
    [No Abstract]   [Full Text] [Related]  

  • 6. The saga of the duration of dual antiplatelet therapy after drug-eluting stent placement.
    Helft G
    Arch Cardiovasc Dis; 2015 Oct; 108(10):469-71. PubMed ID: 26432274
    [No Abstract]   [Full Text] [Related]  

  • 7. Aspirin in coronary artery disease: an appraisal of functions and limitations.
    Würtz M
    Dan Med J; 2015 Apr; 62(4):B5011. PubMed ID: 25872543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are at least 12 months of dual antiplatelet therapy needed for all patients with drug-eluting stents? All patients with drug-eluting stents need at least 12 months of dual antiplatelet therapy.
    Brener SJ
    Circulation; 2015 Jun; 131(22):2001-9; discussion 2009. PubMed ID: 26034082
    [No Abstract]   [Full Text] [Related]  

  • 9. Are at least 12 months of dual antiplatelet therapy needed for all patients with drug-eluting stents? Not all patients with drug-eluting stents need at least 12 months of dual antiplatelet therapy.
    Becker RC; Helmy T
    Circulation; 2015 Jun; 131(22):2010-9; discussion 2019. PubMed ID: 26034083
    [No Abstract]   [Full Text] [Related]  

  • 10. Reduced duration of dual antiplatelet therapy using an improved drug-eluting stent for percutaneous coronary intervention of the left main artery in a real-world, all-comer population: Rationale and study design of the prospective randomized multicenter IDEAL-LM trial.
    Lemmert ME; Oldroyd K; Barragan P; Lesiak M; Byrne RA; Merkulov E; Daemen J; Onuma Y; Witberg K; van Geuns RJ
    Am Heart J; 2017 May; 187():104-111. PubMed ID: 28454794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should all stent patients have prolonged dual antiplatelet therapy?
    Kirtane AJ; King SB
    JACC Cardiovasc Interv; 2015 May; 8(6):873-875. PubMed ID: 25999115
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiplatelet therapy for secondary prevention of coronary artery disease.
    Pilgrim T; Windecker S
    Heart; 2014 Nov; 100(22):1750-6. PubMed ID: 25037531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Levine GN; Bates ER; Bittl JA; Brindis RG; Fihn SD; Fleisher LA; Granger CB; Lange RA; Mack MJ; Mauri L; Mehran R; Mukherjee D; Newby LK; O'Gara PT; Sabatine MS; Smith PK; Smith SC
    J Am Coll Cardiol; 2016 Sep; 68(10):1082-115. PubMed ID: 27036918
    [No Abstract]   [Full Text] [Related]  

  • 14. New oral anticoagulants and dual antiplatelet therapy: Focus on apixaban.
    Pelliccia F; Rollini F; Marazzi G; Greco C; Gaudio C; Angiolillo DJ; Rosano G
    Int J Cardiol; 2016 Dec; 225():154-158. PubMed ID: 27723533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dual antiplatelet therapy for treatment and secondary prevention of coronary artery disease: indications, modalities and duration].
    Degrauwe S; Iglesias JF
    Rev Med Suisse; 2016 May; 12(520):1022-6, 1028-34. PubMed ID: 27424342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
    Wenaweser P; Eshtehardi P; Abrecht L; Zwahlen M; Schmidlin K; Windecker S; Meier B; Haeberli A; Hess OM
    Thromb Haemost; 2010 Sep; 104(3):554-62. PubMed ID: 20664903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
    JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on dual antiplatelet therapy for percutaneous coronary intervention.
    Prasad A; Holmes DR
    Heart; 2009 Jun; 95(11):861-5. PubMed ID: 19372090
    [No Abstract]   [Full Text] [Related]  

  • 19. An appraisal of dual antiplatelet therapy with clopidogrel and aspirin for prevention of cardiovascular events.
    Terpening C
    J Am Board Fam Med; 2009; 22(1):51-6. PubMed ID: 19124633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of Different β-Blockers on Platelet Aggregation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy.
    Ignjatovic V; Pavlovic S; Miloradovic V; Andjelkovic N; Davidovic G; Djurdjevic P; Stolic R; Iric-Cupic V; Simic I; Ignjatovic VD; Petrovic N; Smiljanic Z; Zdravkovic V; Simovic S; Jovanovic D; Nesic J
    J Cardiovasc Pharmacol Ther; 2016 Jan; 21(1):44-52. PubMed ID: 25868659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.